V

Viatris

Global pharma selling generics and biosimilars

Business Manager

Full-Time
No salary listed
Mid
Bachelor's
Hatfield, UK
In Person
Sales & Account ManagementField Sales

About the job

Requirements
  • Education to degree level is preferred.
  • A successful track record in a similar role with a commercial mindset is required.
  • Excellent analytical skills and the ability to identify and distil opportunities from complex sets of data are required.
  • Strong project management and presentation skills are required.
  • A full, clean driving licence is required.
Responsibilities
  • Take strategic and operational accountability for account management of Viatris promoted branded products within a defined geographical territory and specified timelines.
  • Deliver agreed sales objectives and resulting product sales growth while adhering to the ABPI Code of Conduct.
  • Develop effective customer relationships with key stakeholders across NHS environments, including integrated care boards, tertiary care, secondary care, and primary care.
  • Build key relationships with relevant stakeholders in target accounts.
  • Identify and assess business opportunities from complex data sets.
  • Formulate strategic account plans based on data, local NHS knowledge, and insights.
  • Construct joint customer plans with key stakeholders using a solution-focused approach.
  • Select target accounts and customer groups in discussion with the Regional Business Manager.
  • Take exclusive responsibility for target customers within a defined territory.
  • Maintain a forward-looking view of how the business can adapt to the evolving NHS at population-health level and across integrated care systems and integrated care boards.
Desired Qualifications
  • A forward-looking perspective on how the business can pivot to meet the needs of the evolving NHS at population-health level and across integrated care systems and integrated care boards.

About the company

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Get referred to Viatris

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue rose 5% to $3.8 billion, and guidance increased.
  • Debt fell after $900 million repayment, reducing gross leverage to 2.9x.
  • Tyrvaya divestiture, Gwyn Lo, and meloxicam NDA support a higher-value portfolio shift.

What critics are saying

  • Nashik fire and FDA Form 483 disruptions cut second-half 2026 revenue by $100-$150 million.
  • Greater China procurement changes pressure hospital volumes, squeezing one of Viatris's fastest growth engines.
  • Generic pricing MDL and ongoing patent fights in Japan keep legal overhangs persistent.

What makes Viatris unique

  • Viatris pairs 165-country reach with complex generics, branded drugs, and biosimilars.
  • Japan approved WAKIX on September 16, 2026, expanding first-in-class sleep medicine reach.
  • FDA approved Gwyn Lo on July 29, 2026, adding a differentiated women’s health product.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Wellness Program
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

18%

1 year growth

18%

2 year growth

18%
PR Newswire
Oct 16th, 2026
Viatris wins FDA approval for Ryzumvi to treat presbyopia in adults

Viatris has won US Food and Drug Administration (FDA) approval for RYZUMVI (phentolamine ophthalmic solution 0.75%) to treat presbyopia in adults, the company announced on October 16, 2026. RYZUMVI was already approved in the US for pharmacologically-induced mydriasis, and is the only commercially available FDA-approved product for that use. The new approval adds presbyopia to its indications. Viatris is exploring a US partner to commercialise the product for presbyopia. Under a global licensing agreement with Opus Genetics, Viatris holds exclusive US commercial rights. Presbyopia is the gradual loss of near focusing ability with age, typically noticeable in the early to mid-40s.

South Jordan Journal
Oct 8th, 2026
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

The South Jordan Journal is the local newspaper covering news and events in the City of South Jordan, Utah. The South Jordan Journal provides one of the best advertising channels to the residents of the City of South Jordan.

Yahoo Finance
Sep 24th, 2026
Viatris stock surges 78% in a year, outpacing S&P 500 with strong portfolio growth

Viatris Inc., a global pharmaceutical company based in Canonsburg, Pennsylvania, has significantly outperformed the S&P 500. The stock surged 8.7% over the past three months, compared to the index's 4.7% gain. Year to date, shares climbed 37.5%, whilst the S&P 500 rose 12.6%. With a market cap of $10.4 billion, Viatris operates in 165+ countries and covers more than 10 major therapeutic areas. The company sells more than 80 billion doses annually across 1,400 approved molecules. On 16 September, shares jumped 2.2% after Japan approved WAKIX for treating excessive daytime sleepiness. The company's strong performance stems from improved business momentum, solid cash generation, and progress in its higher-value product portfolio.

PR Newswire
Sep 16th, 2026
Japan approves Viatris' Wakix for narcolepsy and sleep apnoea-related daytime sleepiness

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for WAKIX (pitolisant) to treat excessive daytime sleepiness associated with obstructive sleep apnea syndrome and narcolepsy. WAKIX is the first histamine H3 receptor antagonist/inverse agonist approved in Japan for these conditions. The treatment addresses excessive daytime sleepiness, a symptom affecting both conditions that can significantly impact daily functioning and quality of life. WAKIX is not classified as a controlled substance and has been designated an orphan drug in Japan for narcolepsy. The approval was supported by positive data from domestic Phase 3 clinical trials in Japan and international studies. WAKIX, discovered by Bioprojet and licensed to Viatris for Japan, has previously received approvals in more than 38 countries for narcolepsy.

Yahoo Finance
Aug 13th, 2026
Viatris delivers $3.8B revenue with 3.5% growth, raises outlook after strong Q2 2026

Viatris reported strong Q2 2026 results, with total revenues of $3.8 billion, representing 3.5% operational growth year-over-year. The pharmaceutical company posted adjusted EBITDA of $1.2 billion and adjusted earnings per share of $0.69. CEO Scott Smith highlighted strong commercial performance across the company's global portfolio, particularly in Greater China where investments in established brands drove meaningful growth. North America also saw solid growth from complex generics and transdermal products. The company announced US regulatory approval for Gwyn Lo last week, with a launch planned for later this year. Fast-acting meloxicam continues through FDA review, with launch preparations underway. Based on the strong quarterly performance, Viatris raised its outlook for the remainder of 2026. The results exceeded company expectations and demonstrated continued improvement in operating leverage.